Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

Oncology Letters

Volumn 9, Issue 2, 2015, Pages 785-789

  Yuan, Kai ^a   Wu, Hongyan ^a   Wang, Yulong ^a   Chen, Hongqiang ^a   Jiao, Mingwen ^a   Fu, Rongzhan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Phosphoinositol 3 kinase; Phosphorylation; Progression; Proline rich Akt substrate of 40 kDa; Trastuzumab resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GENOMIC DNA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHO PRAS40; PROGESTERONE RECEPTOR; PROTEIN SERINE THREONINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ALLELE SPECIFIC POLYMERASE CHAIN REACTION; ARTICLE; BREAST METASTASIS; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84918841143     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2744     Document Type: Article

References (19)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
3. Huang Y, Fu P and Fan W: Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer. Current Drug Targets 14: 889-898, 2013.
4. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
5. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402, 2007.
6. Razis E, Bobos M, Kotoula V, et al: Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128: 447-456, 2011.
7. Andersen JN, Sathyanarayanan S, Di Bacco A, et al: Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Science Transl Med 2: 43ra55, 2010.
8. Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177: 1647-1656, 2010.
9. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
10. Zhang L, Shi L, Zhao X, Wang Y and Yue W: PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther 6: 497-502, 2013.
11. Lu YZ, Deng AM, Li LH, et al: Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer. Arch Med Sci 10: 149-153, 2014.
12. Fu R: Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer. Asian Biomedicine (Research Reviews and News) 6: 573-577, 2012.
13. Saal LH, Holm K, Maurer M, et al: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559, 2005.
14. Eichhorn PJ, Gili M, Scaltriti M, et al: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68: 9221-9230, 2008.
15. Wang Q, Ding H, Liu B, et al: Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors. Int J Oncol 44: 1277-1283, 2014.
16. Fountzilas G, Christodoulou C, Bobos M, et al: Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med 10: 212, 2012.
17. Minuti G, Cappuzzo F, Duchnowska R, et al: Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 107: 793-799, 2012.
18. Wang H, Zhang Q, Wen Q, et al: Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal 24: 17-24, 2012.
19. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440, 2009.